PTCT earnings analysis
What we found in PTCT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
PTC Therapeutics reported strong Q1 2026 results with total revenue of $272.6 million, exceeding estimates of $227.5 million. The EPS of -$0.03 significantly beat the projected -$0.41. Management highlighted improvements in product performance, particularly from the Sephience launch, and adjusted full-year revenue guidance upward to a range of $1.08 billion to $1.18 billion.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 Revenue Beats Expectations
- Actual revenue was $272.6 million, beating estimates by 19.8%.
- Significant EPS Surprise
- Reported EPS of -$0.03 compared to an estimate of -$0.41, presenting a 92.7% positive surprise.
- Guidance Raised for FY 2026
- Full-year revenue guidance increased to between $1.08 billion and $1.18 billion.
- Strong Growth from Sephience Launch
- Sephience contributed positively to revenue growth in Q1.
- Robust Cash Position
- Cash, cash equivalents, and marketable securities totaled $1.89 billion as of March 31, 2026.
- Positive Segment Performance
- Revenue from key therapeutic segments showed strong growth.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operating Cash Burn
- Net cash used in operating activities was $59 million, contrasting sharply with $870 million provided in the same quarter last year.
- Dependence on Product Sales
- Future revenue growth heavily depends on successful commercialization efforts amidst competitive pressures.
- Regulatory Approval Uncertainties
- Ongoing trials and required studies for NDA resubmission may delay product launches, impacting revenue timelines.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.03
What they said about what is next.
Management increased the outlook for 2026 revenue based on improved product performance.
The filing reads better than the one before it.
What came before.
- 10-K · February 19, 2026
- PTC’s 2025 results show a volatile year driven by a $1.18B Q1 revenue spike and otherwise weak commercial quarters; Q4 revenue was $164,677,000 with GAAP diluted EPS of $(1.67), missing consensus. The filing emphasizes…
- 10-Q · November 4, 2025
- PTC reported Q3 2025 revenue of $211,007,000 (up from $196,786,000 year-over-year and above consensus) and GAAP diluted EPS of $0.20 (vs $(1.39) in Q3 2024). The quarter was driven by higher royalty revenue…
- 10-Q · August 7, 2025
- PTC reported Q2 2025 revenue of $178.875M and GAAP diluted loss per share of $(0.83). Revenue declined modestly year-over-year (down $7.829M, -4.2%) but collapsed sequentially from Q1 2025 due to the absence of large…
- 10-Q · November 7, 2024
- PTC reported Q3 revenue of $196.8M, essentially flat versus $196.6M in Q3 2023, with a narrower operating loss of $54.5M (vs. $118.2M) and GAAP EPS of -$1.39 (improved from -$1.76). Royalty revenue grew materially while…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PTCT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever